Bioversys AG
Research Bioversys AG (BIOV) on Bullrun: market cap CHF 145.46M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIOV
- ExchangeSW
- CountrySwitzerland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCHF
- Market capCHF 145.46M
- Financial periodFY2025
- RevenueCHF 800.00K
- Net income-CHF 21.83M
- Free cash flow-CHF 22.16M
- Gross margin-386.6%
Valuation Snapshot
latest market cap is CHF 145.46M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CHF 800.00K | -CHF 21.83M | -CHF 22.16M | -386.6% | -3.89 | CHF 82.51M | CHF 21.73M | CHF 59.81M |
| FY2024 | CHF 0 | -CHF 18.72M | -CHF 15.61M | n/a | -3.16 | CHF 26.62M | CHF 16.97M | CHF 10.68M |
| FY2023 | n/a | -CHF 18.30M | n/a | n/a | n/a | CHF 24.38M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | CHF 145.46M | n/a | n/a | n/a |
About Bioversys AG
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Bioversys AG's market cap?
Bioversys AG's market capitalization is CHF 145.46M.
What does Bioversys AG do?
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd.